Table 2 ERK-related signaling after repeated alprazolam (ALP) treatment within the ventral tegmental area (VTA) and nucleus accumbens (NAc) 24 h or 1 month after the last injection.
Treatment | Interval | Brain region | Gene | mRNA ΔΔC(t) | Protein phosphorylation (phospho/total) | |
|---|---|---|---|---|---|---|
Repeated | ALP | 24 h | VTA | ERK1 | ↓ | ↑ |
Repeated | ALP | 24 h | VTA | ERK2 | ↓ | ↑ |
Repeated | ALP | 24 h | VTA | CREB | ↓ | ↑ |
Repeated | ALP | 24 h | VTA | AKT | ↓ | ↑ |
Repeated | ALP | 24 h | NAc | ERK1 | ↑ | ↑ |
Repeated | ALP | 24 h | NAc | ERK2 | ↑ | ↑ |
Repeated | ALP | 24 h | NAc | CREB | ↑ | < > |
Repeated | ALP | 24 h | NAc | AKT | ↑ | ↑ |
Repeated | ALP | 1 month | VTA | ERK1 | ↓ | < > |
Repeated | ALP | 1 month | VTA | ERK2 | ↓ | < > |
Repeated | ALP | 1 month | VTA | CREB | ↓ | ↑ |
Repeated | ALP | 1 month | VTA | AKT | ↓ | ↓ |
Repeated | ALP | 1 month | NAc | ERK1 | ↓ | ↓ |
Repeated | ALP | 1 month | NAc | ERK2 | ↓ | ↓ |
Repeated | ALP | 1 month | NAc | CREB | ↓ | < > |
Repeated | ALP | 1 month | NAc | AKT | ↓ | ↓ |
